Sociedad Americana de Hirudoterapia

Cervicogenic Headache

Investigational adjunct for cervicogenic headache referred from upper cervical (C1-C3) joints; case-series evidence for pain reduction.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for cervicogenic headache. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
¿Qué evidencia existe?
Tier C (investigational). There are no published controlled trials. Evidence-based care for cervicogenic headache (unilateral headache referred from cervical spine structures): structured physical therapy with cervical and thoracic mobilization, suboccipital stretching, cervical strengthening, postural correction, manual therapy combined with exercise (the strongest RCT support), occipital nerve block or facet joint injection for diagnostic and therapeutic purposes, and (refractory) radiofrequency ablation of medial branch nerves. NSAIDs and muscle relaxants help short-term. Workup must exclude secondary headache causes.
Riesgos principales
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising over the upper trapezius or suboccipital region for 5 to 10 days
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • Temporary worsening of headache for 1 to 3 days from local irritation
  • RISK if leech is misplaced near the carotid sheath, vertebral artery course, or anterior neck
  • Delay of evidence-based physical therapy and occipital nerve block
  • Placebo response masking secondary headache causes (intracranial pathology, giant cell arteritis, cervical spine tumor)
Quién no debería considerar esto
  • Patients with red-flag headache features (thunderclap onset, neurological deficits, fever with stiff neck, age over 50 with new-onset headache, immunosuppression, cancer history)
  • Patients with suspected migraine, cluster headache, or tension-type headache (different treatment paths)
  • Patients who have not completed a structured physical therapy program with manual therapy and exercise
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with cervical instability, recent neck trauma, or vertebrobasilar insufficiency
  • Patients with active dermatitis or broken skin over the cervical or suboccipital region
Qué preguntar a su clínico
  • Have we excluded migraine, cluster headache, tension-type headache, and secondary headache causes?
  • Have I had imaging if there are any red flags or atypical features?
  • Have I completed a structured physical therapy program with manual therapy and cervical strengthening?
  • Have I tried occipital nerve block or facet joint injection - both diagnostic and therapeutic?
  • Am I a candidate for radiofrequency ablation of medial branch nerves for refractory cases?
  • Where exactly will leeches be placed - confirm strictly over upper trapezius or suboccipital region, NEVER on anterior neck?
  • What is the Aeromonas-prevention protocol?
Cuándo buscar atención urgente
  • Thunderclap (worst-of-life) headache, sudden severe headache (possible subarachnoid hemorrhage - 911)
  • Headache with fever, stiff neck, photophobia, or altered mental status (possible meningitis)
  • Sudden vision change, speech difficulty, focal weakness, or seizure
  • Jaw claudication, scalp tenderness, or vision change in age over 50 (possible giant cell arteritis)
  • New-onset headache during pregnancy or postpartum
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or throat swelling, or breathing difficulty

Qué NO significa esto

  • This is not FDA-cleared for cervicogenic headache.
  • No controlled trials support efficacy; cervicogenic headache responds best to manual therapy plus exercise.
  • It does not replace occipital nerve block or facet joint injection - both have stronger evidence and are diagnostic.
  • It does not address red-flag features that require imaging and specialist referral.
  • Headache types overlap; misdiagnosis is common and treatment of the wrong type wastes time.

Clinical Profile

Category
neurological
ICD-10
G44.86, M54.2
Safety tier
medium

Evidence Summary

Cervicogenic headache is defined per ICHD-3 criteria as headache caused by a disorder of the cervical spine and its component bony, disc, or soft-tissue elements (most commonly the C1-C3 zygapophyseal joints). Diagnosis is supported by a diagnostic anesthetic block. Conventional management includes manual therapy, motor-control exercises, and image-guided cervical facet or C2 dorsal ramus block. No controlled clinical trial or published case series of leech therapy for cervicogenic headache has been reported; any use is investigational and mechanistic only and should not replace established care.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Ahmed I et al. (2020), n=24

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Vertebrobasilar insufficiency
  • Cervical instability (Down syndrome, RA, traumatic ligamentous injury)
  • Recent cervical facet injection (<4 weeks)

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Cervicogenic Headache — Hirudotherapy Evidence | ASH